Abstract
ignificant pulmonary regurgitation (PR) is common after surgical or percutaneous treatment of pulmonary stenosis and tetralogy of Fallot (TOF) and leads to significant late morbidity and mortality. Optimal timing of pulmonary alve replacement (PVR) and procedures minimizing surgical trauma re therefore important. The new Shelhigh Injectable Stented Pulonic Valve NR4000-PA MIS (Shelhigh Inc, Union, NJ) offers the ossibility of PVR without cardiopulmonary bypass (CPB). Here we eport our early experience with the first clinical use of this new evice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Thoracic and Cardiovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
